A novel approach to develop anti-virulence agents against group A streptococcus.
Department of Internal Medicine, University of Missouri Hospital and Clinics, Columbia, MO, USA.
Yuanxi
Y
Xu
Yibao
Y
Ma
Hongmin
H
Sun
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015964:Gene Expression Regulation, Bacterial / Q000187:drug effects; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D011799:Quinazolines / Q000494:pharmacology; D013290:Streptococcal Infections / Q000382:microbiology; D013297:Streptococcus pyogenes / Q000187:drug effects / Q000235:genetics / Q000472:pathogenicity*; D013300:Streptokinase / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D014774:Virulence; D037521:Virulence Factors / Q000037:antagonists & inhibitors* / Q000378:metabolism*
D000900:Anti-Bacterial Agents; C571730:CCG-2979; D004791:Enzyme Inhibitors; D011799:Quinazolines; D037521:Virulence Factors; D013300:Streptokinase